accountGlaxoSmithKline is seeing strong growth from sales in emerging markets, offsetting declines in the U.S. and Europe from competition by generic drugs, Chief Executive Andrew Witty told CNBC Tuesday. Glaxo...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Emerging-Markets Business Offsets Generics: Glaxo CEO
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account